Patient Portal Health Professionals

We found you in South Australia Ok thanks

Change your preferred state

Close

Our Science (More Information)

Print

Preimplantation Genetic Screening (PGS)

The screening test is available to at-risk couples, and is able to screen all 23 pairs of chromosomes to ensure only embryos with a normal chromosome complement are selected for transfer. The test is able to measure whole chromosome copy imbalances, as well as specific structural chromosome rearrangements, from a single embryo cell.

We have recently reviewed our PGS fees to ensure this service is accessible to all patients.  Under our new fee arrangements PGS could be as little as $840 per cycle.

How is the screening performed?

During an IVF cycle, patient’s embryos are assessed for biopsy on days 4 or 5. During biopsy a single cell or cells are removed from the embryo. Following the embryo biopsy, embryos are cryopreserved and the testing is performed on the biopsied cell(s). The screening is performed in-house in the Repromed laboratories.

Following the screening, patients are able to have euploid (normal) embryos transferred in a frozen embryo transfer cycle. We have found that on average 30.3% of embryos are suitable for transfer.

How does maternal age influence aneuploidy?

Chromosome aneuploidy (abnormal number of chromosomes) is a major cause of IVF failure, pregnancy loss, and in rare cases abnormal pregnancy and live birth. Most aneuploidies arise in the final stages of egg development and increase exponentially with maternal age. The percentage of aneuploid embryos is known to increase with maternal age, however, it may occur in embryos from couples of all ages.

What are the success rates?

A recent randomised prospective IVF study has shown that selectively implanting euploid (normal) embryos following screening with PGS can increase pregnancy rates by up to 65% (Yang et al, 2012. Molecular Cytogenetics).

It is important that each couple has their individual risk assessed by a fertility specialist before determining if PGS should be incorporated into their IVF treatment plan.

More information for AMH

Why have this test?

AMH is produced by the granulosa cells in the developing early antral follicles of the ovary. As a women runs out of eggs the number of small antral follicles declines and do does the AMH thereby making AMH a clinically useful measure of ovarian reserve. Many women delay starting a family for various reasons. However, fertility declines with age and problems may develop. An early indication of fertility status may help in deciding whether to start a family sooner or later.

What if your Ovarian Reserve is low?

Once the ovary runs out of eggs, the body isn’t able to produce any more, and usually remaining eggs are of lesser quality. Even IVF treatment will not dramatically improve fertility if there are only a few poor quality eggs left within the ovaries. If you are in a relationship and have a low ovarian reserve, the best option is to go ahead and try for children as soon as possible. If a woman does undergo premature menopause, using donor eggs is a viable option that is available through Repromed.

Who is at risk of low AMH?

You may be at increased risk of having a low AMH if you have;

  • a family history of early menopause or reduced AMH
  • had surgery to the ovary
  • severe endometriosis
  • had previous chemotherapy or radiotherapy.

 

Please call Repromed on (08) 8333 8111 for further information on our PGS technology.

(Complete the form and one of our staff will be in touch with you soon)

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.